Grace Therapeutics, Inc. Earnings Per Share, Basic and Diluted
Grace Therapeutics, Inc. (GRCE) reported Earnings Per Share, Basic and Diluted of -$0.27 per share for the 12-month period ending 2022-03-31, per its 10-K filed 2022-06-21.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-06-21
- Grace Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.06.
- Grace Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.09.
- Grace Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was $0.03.
- Grace Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.01.
- Grace Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2022 was -$0.27.
- Grace Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2021 was -$1.33.
- Grace Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$0.30.
- Grace Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2019 was -$0.73.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 3 month as first filed | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 6 month as first filed | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 9 month as first filed | Earnings Per Share, Basic and Diluted 12 month | Earnings Per Share, Basic and Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-03-31 | -$0.06 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$0.13 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$0.14 derived: net income ÷ weighted average shares · filed 2023-06-23 | -$0.27 10-K · filed 2022-06-21 | ||||
| 2021-12-31 | -$0.09 10-Q · filed 2022-02-14 | -$0.07 derived: net income ÷ weighted average shares · filed 2023-02-14 | -$0.23 10-Q · filed 2022-02-14 | -$0.15 derived: net income ÷ weighted average shares · filed 2023-02-14 | ||||
| 2021-09-30 | $0.03 10-Q · filed 2021-11-10 | -$0.13 10-Q · filed 2021-11-10 | -$0.09 derived: net income ÷ weighted average shares · filed 2023-02-14 | -$0.16 derived: net income ÷ weighted average shares · filed 2023-02-14 | ||||
| 2021-06-30 | -$0.01 10-Q · filed 2021-08-12 | -$0.08 derived: net income ÷ weighted average shares · filed 2023-02-14 | -$0.15 derived: net income ÷ weighted average shares · filed 2023-02-14 | -$0.28 derived: net income ÷ weighted average shares · filed 2023-02-14 | ||||
| 2021-03-31 | -$0.24 derived: net income ÷ weighted average shares · filed 2022-06-21 | -$0.49 derived: net income ÷ weighted average shares · filed 2022-06-21 | -$0.94 derived: net income ÷ weighted average shares · filed 2022-06-21 | -$1.33 10-K · filed 2022-06-21 | -$0.17 10-K · filed 2021-06-22 | |||
| 2020-12-31 | -$0.26 10-Q · filed 2022-02-14 | -$0.03 10-Q · filed 2021-02-09 | -$0.77 derived: net income ÷ weighted average shares · filed 2022-02-14 | -$1.18 10-Q · filed 2022-02-14 | -$0.15 10-Q · filed 2021-02-09 | -$0.77 derived: net income ÷ weighted average shares · filed 2022-02-14 | ||
| 2020-09-30 | -$0.52 10-Q · filed 2021-11-10 | -$0.06 10-Q · filed 2020-11-16 | -$0.93 10-Q · filed 2021-11-10 | -$0.11 10-Q · filed 2020-11-16 | -$0.57 derived: net income ÷ weighted average shares · filed 2022-02-14 | -$0.69 derived: net income ÷ weighted average shares · filed 2022-02-14 | ||
| 2020-06-30 | -$0.05 10-Q · filed 2021-08-12 | -$0.33 derived: net income ÷ weighted average shares · filed 2022-02-14 | -$0.47 derived: net income ÷ weighted average shares · filed 2022-02-14 | -$0.72 derived: net income ÷ weighted average shares · filed 2022-02-14 | ||||
| 2020-03-31 | -$0.28 derived: net income ÷ weighted average shares · filed 2021-06-22 | -$0.43 derived: net income ÷ weighted average shares · filed 2021-06-22 | -$0.68 derived: net income ÷ weighted average shares · filed 2021-06-22 | -$0.30 10-K · filed 2021-06-22 | ||||
| 2019-12-31 | -$0.14 10-Q · filed 2021-02-09 | -$0.39 derived: net income ÷ weighted average shares · filed 2021-02-09 | -$0.51 10-Q · filed 2021-02-09 | |||||
| 2019-09-30 | -$0.25 10-Q · filed 2020-11-16 | -$0.37 10-Q · filed 2020-11-16 | ||||||
| 2019-06-30 | -$0.11 10-Q · filed 2020-08-13 | |||||||
| 2019-03-31 | -$0.73 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |